NORRIS MEDICINES LTD.

Norris Medicines Ltd has announced the closure of its trading window for designated persons, including promoters, directors, auditors, and key managerial personnel, effective July 1, 2026. This closure is in accordance with the company's code of conduct for prohibiting insider trading, aligned with SEBI regulations. The trading window will reopen 48 hours after the public declaration of the un-audited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to approve these results will be communicated separately. During the closure, all designated individuals are prohibited from trading in the company's securities.

Norris Medicines Ltd has appointed M/s. Dhiren Y Parikh & Co., Chartered Accountants, as Internal Auditors for the FY 2026-2027. This decision was made during the Board Meeting held on May 30, 2026, where the audited financial results for the quarter and year ended March 31, 2026, were also approved. The board meeting commenced at 03:00 p.m. and concluded at 03:30 p.m.

Norris Medicines Ltd's Board of Directors approved the audited financial results along with the audit report for the quarter and year ended March 31, 2026. The board also approved the appointment of M/s. Dhiren Y Parikh & Co. as Internal Auditors for FY 2026-2027. The meeting commenced at 03:00 p.m. and concluded at 03:30 p.m.

Norris Medicines Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. The board also approved the appointment of M/s. Dhiren Y Parikh & Co. as Internal Auditors for FY 2026-2027. The meeting commenced at 03:00 p.m. and concluded at 03:30 p.m.

Norris Medicines Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The meeting will also address any other business with the permission of the Chair and the consent of the Directors. The trading window for dealing in the company's securities is closed from April 1, 2026, until 48 hours after the declaration of the financial results.

Norris Medicines Ltd has announced the closure of its trading window for designated persons, including promoters, directors, auditors, key managerial personnel, and their immediate relatives. The closure will take effect from Wednesday, 1st April, 2026, and will remain in force until 48 hours after the declaration of audited financial results for the quarter and year ended 31st March, 2026. The date of the board meeting for the approval of the audited financial results will be intimated in due course.

Norris Medicines Ltd has approved the Un-Audited Financial Results for the quarter and year ended 31st December, 2025. The Board of Directors considered and approved these results in a meeting held on 14th February, 2026. The results will be published in newspapers as per the prescribed format under Regulation 47 of Listing Regulations.

Norris Medicines Ltd. announced the approval of their un-audited financial results for the quarter and nine months ended 31st December, 2025 during a Board Meeting held on 14th February, 2026. The meeting was conducted from 3:15 PM to 3:45 PM IST. The company will publish the financial results in newspapers as per Regulation 47 of the Listing Regulations.

Norris Medicines Ltd informs that the reclassification application of Promoter shareholders to the Public category, submitted pursuant to Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been closed by BSE Limited on 12.02.2026. The closure is due to non-payment of disputed penalty, resulting in the existing classification of the shareholders to continue unchanged. The shareholding pattern of the Company remains unaltered. This intimation is made pursuant to Regulation 30 read with Schedule III, Part A, Para A of the SEBI Listing Regulations.

Norris Medicines Ltd has announced that its Board of Directors will meet on February 14, 2026, to consider and approve the un-audited financial results for the quarter ended 31st December 2025. The meeting will be held at the company's registered office in Ankleshwar, Gujarat. The trading window for dealing in securities of the company is closed from January 01, 2026, until 48 hours after the declaration of the un-audited financial results.